Research Study

Nifty Biosimilar

Format: PDF file | Document type: Research Study | Promoted Content

This content is provided by UGA Biopharma, and any views and opinions expressed do not necessarily reflect those of

Nifty Biosimilar

Aflibercept (Zaltrap®)​ is a recombinant fusion protein with complex post-translational modifications. Therefore  deep understanding of biosimilar development is required to develop a biosimilar like Aflibercept.

UGA Biopharma​ has successfully completed a large number of biosimilar for several international biopharmaceutical companies. Our know-how and longstanding expertise in cell line development, bioprocess optimization, downstream development and analytics makes us the leading partner for your biosimilar development projects

Supplier info centre